Teng Zhu1, Qinqin Han1, Xiaoxiao Zhang2, Qiuzhong Hou3. 1. Department of Cadiovascular Medicine, Shengli Oilfield Central Hospital Dongying 257000, Shandong, China. 2. Ward of General Practice Department, Shengli Oilfield Central Hospital Dongying 257000, Shandong, China. 3. Dongying Hospital of Traditional Chinese Medicine (Shengli Hospital) Dongying 257000, Shandong, China.
Abstract
OBJECTIVE: To explore the effect of combin3e uw3 of Xinnaoning and trimetazidine on the levels of creatine kinase (CK) and its isoenzymes (CK-MB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) in patients with myocardial ischemia (MI). METHODS: A total of 137 patients with MI admitted to our hospital were enrolled in our study. Among them, 68 cases in the control group (CG) were treated with trimetazidine and 69 cases in the study group (SG) were treated with Xinnaoning on the basis of the CG. The incidence of adverse events, serum CK, CK-MB, AST, ALT, LDH levels, episodes of angina, lipid levels [total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)], and quality of life (SF-36) scores were compared between the two groups. RESULTS: The total effective rate was 88.41% in the SG, which was higher than 73.53% in the CG (P < 0.05). The episodes of angina in the SG were lower than those in the CG after 3 months of treatment (P < 0.05). The SG showed decreased serum CK, CK-MB, AST, and ALT and LDH levels compared with the CG (P < 0.05). The SG showed increased EF, SV and CO levels compared with the CG after 3 months of treatment. The SG also exhibited lower TC, TG and LDL-C, and higher HDL-C and quality of life than the CG after 3 months of treatment (P < 0.05). CONCLUSION: The regimen of Xinnaoning and trimetazidine could significantly improve cardiac function and serum cardiac enzyme levels, reduce lipid levels, and improve the quality of life in patients with MI. AJTR
OBJECTIVE: To explore the effect of combin3e uw3 of Xinnaoning and trimetazidine on the levels of creatine kinase (CK) and its isoenzymes (CK-MB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) in patients with myocardial ischemia (MI). METHODS: A total of 137 patients with MI admitted to our hospital were enrolled in our study. Among them, 68 cases in the control group (CG) were treated with trimetazidine and 69 cases in the study group (SG) were treated with Xinnaoning on the basis of the CG. The incidence of adverse events, serum CK, CK-MB, AST, ALT, LDH levels, episodes of angina, lipid levels [total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)], and quality of life (SF-36) scores were compared between the two groups. RESULTS: The total effective rate was 88.41% in the SG, which was higher than 73.53% in the CG (P < 0.05). The episodes of angina in the SG were lower than those in the CG after 3 months of treatment (P < 0.05). The SG showed decreased serum CK, CK-MB, AST, and ALT and LDH levels compared with the CG (P < 0.05). The SG showed increased EF, SV and CO levels compared with the CG after 3 months of treatment. The SG also exhibited lower TC, TG and LDL-C, and higher HDL-C and quality of life than the CG after 3 months of treatment (P < 0.05). CONCLUSION: The regimen of Xinnaoning and trimetazidine could significantly improve cardiac function and serum cardiac enzyme levels, reduce lipid levels, and improve the quality of life in patients with MI. AJTR